TranspireBio CEO Presents Industry Perspective on FDA's Updated Bioequivalence Framework at FDA/CRCG Workshop

Summary

TranspireBio Holdings CEO presented the company's perspective on FDA's updated bioequivalence framework at an FDA/CRCG workshop. The announcement represents a routine industry conference participation with no material clinical or regulatory developments disclosed.